Fudan-Zhangjiang Bio-Pharma all set for Star board dual-listing

Science_testing_230x150
By Jonathan Breen
06 Apr 2020

Hong Kong-listed Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has won approval from Shanghai’s bourse to list shares on the Star board.

It has received the go ahead from the Shanghai Stock Exchange (SSE) to float on its Science and Technology Innovation Market (Star) — a Nasdaq-style board for new economy firms, the company said on Monday.

Fudan-Zhangjiang is not alone in aiming for a Star dual-listing. Last week, HKEX-traded ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial